key: cord-0931146-0trroh2w
authors: Liu, Jiao; Chen, Yizhu; Li, Ranran; Wu, Zhixiong; Xu, Qianghong; Li, Zhongyi; Annane, Djillali; Feng, Huibin; Huang, Sisi; Guo, Jun; Zhang, Lidi; Ye, Xiaofei; Zhu, Wei; Du, Hangxiang; Liu, Yong’an; Wang, Tao; Chen, Limin; Wen, Zhenliang; Teboul, Jean-Louis; Chen, Dechang
title: Intravenous immunoglobulin treatment for patients with severe COVID-19: a retrospective multi-center study
date: 2021-05-19
journal: Clin Microbiol Infect
DOI: 10.1016/j.cmi.2021.05.012
sha: 64514daf01f7570eb6fd51c3dacac208de8a29c3
doc_id: 931146
cord_uid: 0trroh2w

OBJECTIVES: Intravenous immunoglobulin (IVIG) is commonly used to treat severe COVID-19, although the clinical outcome of such treatment remains unclear. This study evaluated the effectiveness of IVIG treatment in severe COVID-19 patients. METHODS: This retrospective multicenter study evaluated 28-day mortality in severe COVID-19 patients with or without IVIG treatment. Each patient treated with IVIG was matched with one untreated patient. Logistic regression and inverse probability weighting(IPW)was used to control confounding factors. RESULTS: The study included 850 patients (421 IVIG treated patients and 429 non-IVIG treated patients). After matching, 406 patients per group remained. No significant difference in 28-day mortality was observed after IPW analysis (ATE = 0.008, 95% CI -0.081–0.097, p = 0.863). There were no significant differences between the IVIG group and non-IVIG group for acute respiratory distress syndrome, diffuse intravascular coagulation, myocardial injury, acute hepatic injury, shock, acute kidney injury, non-invasive mechanical ventilation, invasive mechanical ventilation, continuous renal replacement therapy, and extracorporeal membrane oxygenation except for prone position ventilation (ATE = -0.022, 95% CI -0.041– -0.002, p = 0.028). CONCLUSIONS: IVIG treatment was not associated with significant changes in 28-day mortality in severe COVID-19 patients. The effectiveness of IVIG in treating patients with severe COVID-19 needs to be further investigated through future studies.

This multicenter retrospective study evaluated outcomes among patients with severe 1 COVID-19 according to the use or non-use of IVIG treatment. The retrospective study 2 protocol was approved by each hospital's institutional review board, which waived the 3 requirement for informed consent. 4 Adults with confirmed COVID-19, presence of a respiratory rate higher than 30 breaths/min, 5 oxygen saturation less than 93% at rest, PaO2/FiO2 ≤ 300 mmHg, and a lung imaging 6 showing that the lesions had progressed more than 50% within a period of 24-48 hours were 7 included. Patients presenting the following conditions were excluded: pregnancy or lactating, 8 brain dead, allergy to IVIG therapy, or immunoglobulin deficiency. 9

In order to avoid immortal time bias, we matched each patient treated with IVIG with an 10 untreated patient, according to the day of admission for treatment (or lack of treatment). 11

Patients were sorted ascendingly by days spent in the hospital. The following step was to 12 match each IVIG treated patient to an untreated patient who had been in the hospital at least 13 as many days as the time-to-IVIG of the treated patient. In case of multiple matching patients, 14 one untreated matching patient was thus randomly selected. 15

Nasal and pharyngeal swab specimens were collected from patients with an epidemiological 17 history and chest imaging (computed tomography or radiography) that suggested viral 18 pneumonia. The nasopharyngeal swab specimens were subjected to high-throughput 19 sequencing or real-time reverse transcription-polymerase chain reaction to confirm the 20 diagnosis of COVID-19. The clarification of COVID-19 was based on the Chinese 21 management guidelines for COVID-19 (sixth version) [21] . Briefly, patients were diagnosed 22 as severe when: respiratory rate was higher than 30 breaths/min, oxygen saturation less than 23 93% at rest, PaO2/FiO2 ≤ 300mmHg. 24

Diagnosis of acute respiratory distress syndrome (ARDS) was based on the Berlin definition, 25 with a PaO 2 /FIO 2 < 300 mmHg, a positive end-expiratory pressure (PEEP) ≥ 5 cmH 2 O, a 26 decreased light transmittance of both lungs that could not be explained completely by pleural 27 effusion, atelectasis or nodules, and a respiratory failure that could not be explained by heart 1 failure or fluid overload [22] . The definition of diffuse intravascular coagulation (DIC) was 2 based on underlying diseases facilitating its occurrence, clinical symptoms, as well as 3 laboratory indicators [23] . 4

Immunosuppression status was identified on the basis of the presence of malignancy, liver 5 cirrhosis or chronic renal failure as well as the use of immunosuppressive therapy. 6

Immunosuppressive therapy refers to the use of immunosuppressive drugs, such as cytotoxic 7 drugs administered to patients with active tumor, organ transplantation, or HIV, as well as 8 cumulative use of corticosteroids for over three months [24] . 9

Myocardial injury was defined as an increase in troponin concentration above the 99 th 10 percentile upper reference limit (> 0.4 ng/ml) [25, 26] . 11

Patients' medical records were reviewed for the collection of the following variables: age, sex, 13 comorbidities, blood test results, Acute Physiology and Chronic Health Evaluation II 14 (APACHE II) score, Sequential Organ Failure Assessment (SOFA) score, imaging findings, 15 IVIG treatment characteristics (maximum daily dose, duration of treatment), and respiratory 16 support (oxygen therapy, non-invasive mechanical ventilation, invasive mechanical 17 ventilation, prone position ventilation, and extracorporeal membrane oxygenation (ECMO)). 18

Laboratory parameters as well as APACHE II and SOFA scores were assessed upon hospital 19 admission. 20

The primary outcome was defined as 28-day all-cause mortality after propensity matching 22 analysis. The start of the 28 days was defined as day of admission to the hospital. The 23 secondary outcomes were defined as ARDS, DIC, myocardial injury, acute hepatic injury, 24 shock, acute kidney injury (AKI), non-invasive mechanical ventilation, invasive mechanical 25 ventilation, prone position ventilation, continuous renal replacement therapy, and ECMO between the two groups (treated versus untreated patients). 1

Continuous variables were expressed as median (interquartile range (IQR)) and were 3 compared using the Mann-Whitney U test. Categorical variables were expressed as numbers 4 (%) and compared using Fisher's exact test or the Chi-squared test. Missing data was not 5 imputed in this study. Univariate logistic regression analysis was conducted and applied to 6 evaluate possible predictors of 28-day mortality in the matched sample. We included 7 variables associated with the dependent variable in bivariate analysis (p < 0.1) as well as what 8 made clinical sense, without missing data for Multivariate Analysis. We estimated the 9 predictors for 28-day mortality by fitting multivariate logistic regression with random 10 intercepts to account for clustering of the inpatient hospitals. Model fit was evaluated by 11

Hosmer-Lemeshow goodness of fit test. 12

The propensity score method was conducted to evaluate the relationship between IVIG and 13 28-day mortality. The following variables were included in the propensity score: fever, 14 hypertension, corticosteroids (methylprednisolone, dexamethasone, hydrocortisone, and 15 prednisolone), SOFA score, tumor, COPD, chronic cardiac disease, antiviral, chronic liver 16 disease, diabetes, gender, stroke, immunosuppression, age, systolic pressure, chronic kidney 17 disease, APACHE II, and respiratory support. A propensity score density plot was used to 18 illustrate the distribution of propensity score in both groups. Standardized mean difference 19 (SMD) was used to examine the balance of covariate distribution between treatment groups 20 after the propensity score. IPW was performed to adjust the baseline characteristics in the 21 IVIG and non-IVIG groups. Differences were considered statistically significant at p-values 22 of less than 0.05, and all analyses were performed using SPSS software (version 22.0) and 23 Stata software (version16.0).

Mild or moderate disease was observed in 1,496 of the 2,346 patients hospitalized with 1 confirmed COVID-19. The remaining 850 patients were enrolled. Table 1 shows the patients' 2 characteristics and laboratory parameters upon admission. Treatment of IVIG was provided to 3 421 patients (49.5%) and was not provided to 429 patients (50.5%). The median age was 63 4 years (IQR: 55-73 years) and 58.9% of the patients were male. The median SOFA score was 2 5 (IQR: 2-3) and the median APACHE II score was 8 (IQR: 5-9). 406 patients in both groups 6 were matched (see methods). 7

The median duration of IVIG treatment was 9.5 days for all patients (IQR: 4-12 days), 11 9 days for survivors (IQR: 6-15 days) and 7 days for non-survivors (IQR: 3-10 days). The 10 median doses of IVIG were 9.85 g/day for survivors and 10.42 g/day for non-survivors. The 11 median time interval from hospital admission to initiation of IVIG treatment among all 12 patients was 2.8 days (IQR: 1-3 days) (e- Table 1 , e- Figure 1 ). 13 Table 2 shows the preliminary comparison between deaths and survivors at 28 days after 15 matching, as well as the univariable and multi-variable analysis of 28-day mortality with 16 logistic regression. The results of IPW analysis are shown in e- Figure 2 . The common support 17 is shown in e- Figure 2A and SMD is shown in e- Figure 2B . The majority of the SMD was 18 within -10 and 10, indicating that the patients for IPW analysis were well-matched. As shown 19

in Table 3 , after IPW analysis, 28-day mortality between patients in the IVIG and non-IVIG 20 groups was not significantly different. The average treatment effect (ATE) was 0.008 (95% 21 CI -0.081-0.097, p = 0.863). Moreover, logistic regression analysis suggested that the other 22 independent risk factors for 28-day mortality among patients with severe COVID-19 were 23 APACHE II score (odds ratio (OR) = 1.16, 95% CI 1.05-1.18, p < 0.001), age (OR = 1.05, 95% 24 CI 1.03-1.06, p < 0.001), diabetes (OR = 1.98, 95% CI 1.21-3.25, p = 0.003), use of 25 glucocorticoids (OR = 3.00, 95% CI 1.91-4.70, p < 0.001), and SOFA score (OR = 1.54, 95% 26 IVIG treatment were consistent across subgroups except for patients with WBC ≥ 10 (OR = 1 2.21, p = 0.007), with activated partial thromboplastin time (APTT) ≥ 37 (OR = 2.75, p = 2 0.015) and with prothrombin time (PT) ≥ 13.5 (OR = 3.61, p = 0.002) (e- Figure 3 ). 3

As shown in Table 3 , after IPW analysis, except for prone position ventilation (ATE = -0.022, 5 95% CI -0.041--0.002, p = 0.028), there were no significant differences between the IVIG 6 group and non-IVIG group for ARDS, DIC, myocardial injury, acute hepatic injury, shock, 7 AKI, non-invasive mechanical ventilation, invasive mechanical ventilation, continuous renal 8 replacement therapy, and ECMO. 9

This is the first large-cohort retrospective study evaluating the association between IVIG 11 treatment and mortality among a well-defined cohort of patients with severe COVID-19. The 12 results suggest that use of IVIG treatment was not associated with 28-day mortality. 13

The use of IVIG as an adjunctive treatment for sepsis and septic shock has been studied for 14 

The use of IVIG has also been reported in the treatment of several coronavirus-induced 1 infections. Studies of SARS and MERS infection have suggested that IVIG led to a 2 significant improvement in leukocyte and platelet counts although the lack of control group 3 precludes any definitive conclusions [33, 34] . In Wuhan, China, the use of high-dose IVIG 4 treatment (25 g/day for 5 days) plus antivirals (lopinavir/ritonavir) and methylprednisolone 5 for severe COVID-19 has resulted in increased lymphocyte counts, lower concentrations of 6 inflammatory markers, partial/complete resolution of specific lung findings, and negative 7 nasal and oropharyngeal swab test results within a few days of starting treatment [35] . 8

Another treatment of COVID-19 is convalescent plasma. It has been reported that no 9 significant differences were observed in clinical status or overall mortality between patients 10 treated with convalescent plasma and those who received placebo [36] . In addition, the 11 RECOVERY (Randomized Evaluation of COVID-19 Therapy) has shown no effect of 12 convalescent plasma treatment for patients hospitalized with The present study involved a large and well-defined group of patients with severe COVID-19. 14 However, several limitations should be considered. First, retrospective studies are prone to 15 bias and we were unable to compare the results to those from a placebo control group. We 16 cannot clearly indicate why some patients received IVIG and other did not since the decision 17 was left to the discretion of the physician in charge of the patient. Second, there was some 18 heterogeneity in the patient population since some critically ill patients were treated outside 19 the ICU due to a shortage of ICU beds. Third, data collection for the baseline 20 immunoglobulin levels, which may be associated with the efficacy of IVIG, was not available 21 in frontline efforts to fight the pandemic. Fourth, we did not have access to long-term 22 follow-up data or information regarding secondary infections and thrombotic events that were 23 related to the IVIG treatment. Fifth, patients receiving other medical treatments have not been 24 included in our study, probably reducing our estimates of IVIG effect. Sixth, early in the reason for the IVIG use in the clinic, DAG was not used for the selection of relevant variables 1 in the multivariable analysis. We only selected variables with p value less than 0.1 which are 2 also important factors in the clinic for the multivariable analyses. This is a limitation of our 3 study. Nineth, different IVIG dosages were not studied due to the difficulty to ascertain the 4 effect of low vs. high dose IVIG. Tenth, this study is a retrospective study and survival bias 5 exist in our study. Marginal structural model etc. might be a promising tool to address this 6 bias. However, the data in this study have been collected during the early pandemic. There 7 were no medication guidelines, and clinicians prescribed treatment based on their own 8 decisions. Therefore, it is hard to find variables that might prompt patient selection into IVIG 9 treatment, and we matched each patient treated with IVIG with one untreated patient 10 according to the number of days from admission-to-treatment (or lack of treatment). Eleventh, 11 the lack of information on the weight-adjusted doses given to each patient may lead to 12 suboptimal treatment in most patients reported herein, which should be taken into account in 13 future RCT studies. 14 In conclusion, the present study revealed that IVIG treatment was not associated with 15 significant improvements in 28-day mortality in severe COVID-19 patients. In the future, a 16 larger, possibly randomized, study is needed to further investigate the effects of different 17 IVIG dosages in severe COVID-19. 18

None. 20

The authors have no conflicts of interest. immunoglobulin G is not associated with mortality in patients with sepsis and septic shock. Crit Care. 

Creatine kinase

Creatine kinase isoenzyme MB (U/L)

Radiological findings, n (%)